SG Americas Securities LLC Buys 13,058 Shares of Disc Medicine, Inc. $IRON

SG Americas Securities LLC boosted its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 161.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,122 shares of the company’s stock after purchasing an additional 13,058 shares during the quarter. SG Americas Securities LLC owned about 0.06% of Disc Medicine worth $1,677,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd bought a new stake in Disc Medicine during the third quarter worth approximately $38,000. Avanza Fonder AB boosted its position in Disc Medicine by 54.0% during the third quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after purchasing an additional 585 shares during the period. Russell Investments Group Ltd. boosted its position in Disc Medicine by 15,137.5% during the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock worth $161,000 after purchasing an additional 2,422 shares during the period. Bryce Point Capital LLC bought a new stake in Disc Medicine during the third quarter worth approximately $259,000. Finally, Tower Research Capital LLC TRC boosted its position in Disc Medicine by 383.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock worth $211,000 after purchasing an additional 3,152 shares during the period. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Stock Up 1.0%

IRON opened at $65.82 on Tuesday. Disc Medicine, Inc. has a 1-year low of $30.82 and a 1-year high of $99.50. The company has a current ratio of 21.94, a quick ratio of 21.94 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -10.99 and a beta of 0.91. The business has a 50 day moving average of $66.45 and a 200-day moving average of $75.96.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. The firm had revenue of ($19.88) million during the quarter, compared to analyst estimates of $0.15 million. As a group, sell-side analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on IRON shares. UBS Group reaffirmed an “overweight” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Morgan Stanley set a $75.00 price objective on Disc Medicine in a research report on Tuesday, February 17th. BMO Capital Markets reduced their price objective on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a research report on Tuesday, February 17th. Cantor Fitzgerald reduced their price objective on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. Finally, Raymond James Financial reissued a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $104.80.

Insiders Place Their Bets

In related news, insider William Jacob Savage sold 7,378 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $65.88, for a total value of $486,062.64. Following the completion of the transaction, the insider directly owned 85,211 shares in the company, valued at approximately $5,613,700.68. This represents a 7.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Jean M. Franchi sold 7,081 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $65.47, for a total value of $463,593.07. Following the completion of the transaction, the chief financial officer owned 71,343 shares of the company’s stock, valued at $4,670,826.21. The trade was a 9.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 48,022 shares of company stock valued at $3,068,494 in the last ninety days. 3.64% of the stock is currently owned by insiders.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.